The DOI matches its Crossref record; 193 of the 196 references it cites were found in a registry or an index.
Molecular mechanisms of cisplatin resistance
Abstract
Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis. Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure. An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described. Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting molecular circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance). As in some clinical settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clinical implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [9]
In the citing paper
“Mechanistically, cells can prevent cisplatin from reaching and harming DNA by reducing drug uptake, increasing drug efflux, and inactivating the drug through covalent binding to glutathione or metalloproteins [9, 10].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [9]
In the citing paper
“However, mitotic catastrophe appears to constitute a major mechanism of action of anticancer chemotherapeutics, mostly reflecting the increased resistance of neoplastic cells to the induction of intrinsic apoptosis [1004–1009].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [1007]
Citations
Cites
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598
Self-citationAutophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506
Self-citationCisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citation
Flagged first, then by citations
3 of the 196 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T et al. (2001). Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95: 92–95. · DOI
Cited by
Sorted by citations
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citationCisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,816
Mitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B., Kroemer, G., & Galluzzi, L. (2017) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,323
Self-citationZeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,027
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 909
Glutaminolysis: A Hallmark of Cancer Metabolism
Yang, L., Venneti, S., & Nagrath, D. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044546 · Cited by 859
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Self-citationTargeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35259a · Cited by 693
Suraweera, A., O'Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 681
Roh, J.-L., Kim, E. H., Jang, H., & Shin, D. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.010 · Cited by 662
Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Wilson, J. J., & Lippard, S. J. (2013) · Chemical Reviews · doi:10.1021/cr4004314 · Cited by 631
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma
Shao, H., Chung, J., Lee, K., Balaj, L., Min, C., Carter, B. S., Hochberg, F. H., Breakefield, X. O., Lee, H., & Weissleder, R. (2015) · Nature Communications · doi:10.1038/ncomms7999 · Cited by 618
Therapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587
Bernardi, P., Rasola, A., Forte, M. A., & Lippe, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00001.2015 · Cited by 598
Plimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrake, M., Zhou, Y., Serebriiskii, I. G., Slifker, M. J., Alpaugh, K. R., Dulaimi, E., Palma, N. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.009 · Cited by 521
Huang, X., Li, Z., Zhang, Q., Wang, W., Li, B., Wang, L., Xu, Z., Zeng, A., Zhang, X., Zhang, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0969-3 · Cited by 479
Tumor glycolysis, an essential sweet tooth of tumor cells
Paul, S., Ghosh, S., & Kumar, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.007 · Cited by 449
DNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 475
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 457
“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
Davis, A., Tinker, A. V., & Friedlander, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.038 · Cited by 433
Qin, X., Guo, H.-Y., Wang, X.-N., Zhu, X.-Q., Yan, M., Wang, X., Xu, Q., Shi, J.-B., Lu, E., Chen, W., et al. (2019) · Genome Biology · doi:10.1186/s13059-018-1604-0 · Cited by 386
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 422
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 423
Molecular mechanisms of cisplatin resistance in cervical cancer
Zhu, X., Zhu, H., Luo, H., Zhang, W., Shen, Z., & Hu, X. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s106412 · Cited by 412
Haslehurst, A., Koti, M., Dharsee, M., Nuin, P. A. S., Evans, K., Geraci, J., Childs, T. J., Chen, J., Li, J., Weberpals, J. I., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-91 · Cited by 402
DNA repair mechanisms in cancer development and therapy
Torgovnick, A., & Schumacher, B. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00157 · Cited by 427
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S. R., Noubissi, F. K., Ray, P. C., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 415
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Bezu, L., Gomes-da-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J. P., Špíšek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 400
Self-citationLiu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 403
Romani, A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115323 · Cited by 417
The Fanconi Anemia Pathway in Cancer
Joshi, N., Färkkilä, A., & D’Andrea, A. D. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050422 · Cited by 387
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer
Roh, J., Kim, E. H., Jang, H. J., Park, J. Y., & Shin, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.035 · Cited by 383
Copper metabolism as a unique vulnerability in cancer
Shanbhag, V., Gudekar, N., Jasmer, K. J., Papageorgiou, C., Singh, K. D., & Petris, M. J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118893 · Cited by 376
Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin
Aldossary, S. A. (2019) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1608 · Cited by 368
Kim, H., Xu, H., George, E. M., Hallberg, D. L., Kumar, S., Jagannathan, V., Medvedev, S., Kinose, Y., Devins, K. M., Verma, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17127-2 · Cited by 390
YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression
Shi, Y., Fan, S., Wu, M., Zuo, Z., Li, X., Jiang, L., Shen, Q., Xu, P., Zeng, L., Zhou, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12801-6 · Cited by 366
Bonora, M., Wieckowski, M. R., Chinopoulos, C., Kepp, O., Kroemer, G., Galluzzi, L., & Pinton, P. (2015) · Oncogene · doi:10.1038/onc.2014.96 · Cited by 330
Self-citationGboxin is an oxidative phosphorylation inhibitor that targets glioblastoma
Shi, Y., Lim, S. K., Liang, Q., Iyer, S. V., Wang, H.-Y., Wang, Z., Xie, X., Sun, D., Chen, Y.-J., Tabar, V., et al. (2019) · Nature · doi:10.1038/s41586-019-0993-x · Cited by 325
Tan, Y., Li, J., Zhao, G., Huang, K., Cárdenas, H., Wang, Y., Matei, D. E., & Cheng, J. (2022) · Nature Communications · doi:10.1038/s41467-022-32101-w · Cited by 322
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 309
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J. G., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Sautès‐Fridman, C., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 320
Self-citationAnticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium
Konkankit, C. C., Marker, S. C., Knopf, K. M., & Wilson, J. J. (2018) · Dalton Transactions · doi:10.1039/c8dt01858h · Cited by 289
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Meçe, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 288
Self-citationCancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance
Takahashi, N., Chen, H., Harris, I. S., Stover, D. G., Selfors, L. M., Bronson, R. T., Raedt, T. D., Cichowski, K. M., Welm, A. L., Mori, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.001 · Cited by 282
Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., & Zhang, H. (2023) · MedComm · doi:10.1002/mco2.292 · Cited by 315
Vacchelli, E., Senovilla, L., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 270
Self-citationMetallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Cytosolic DNA Sensing in Organismal Tumor Control
Vanpouille-Box, C., Demaria, S., Formenti, S. C., & Galluzzi, L. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.013 · Cited by 250
Self-citationThe state-of-play and future of platinum drugs
Apps, M. G., Choi, E. H. Y., & Wheate, N. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256
Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 260
Self-citationMETTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy
Sun, Y., Shen, W., Hu, S., Lyu, Q., Wang, Q., Wei, T., Zhu, W., & Zhang, J. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02638-9 · Cited by 256
Rossi, A., & Maïo, M. D. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1170596 · Cited by 246
Li, L., He, D., Guo, Q., Zhang, Z., Ru, D., Wang, L., Gong, K., Liu, F., Duan, Y., & Li, H. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01264-5 · Cited by 206
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 231
Self-citationChloroquine and hydroxychloroquine for cancer therapy
Manic, G., Obrist, F., Kroemer, G., Vitale, I., & Galluzzi, L. (2014) · Molecular & Cellular Oncology · doi:10.4161/mco.29911 · Cited by 231
Self-citationCombating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System
Min, Y., Mao, C., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201562 · Cited by 223
Hiley, C. T., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome biology · doi:10.1186/s13059-014-0453-8 · Cited by 233
Linking the future of anticancer metal-complexes to the therapy of tumour metastases
Bergamo, A., & Sava, G. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00134j · Cited by 225
Pink, R. C., Samuel, P., Massa, D., Caley, D. P., Brooks, S. A., & Carter, D. R. F. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.12.042 · Cited by 218
miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2
An, Y., Zhang, Z., Shang, Y., Jiang, X., Dong, J., Yu, P., Nie, Y., & Zhao, Q. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.123 · Cited by 218
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 224
Self-citationLing, X., Chen, X., Riddell, I. A., Tao, W., Wang, J., Hollett, G., Lippard, S. J., Farokhzad, O. C., Shi, J., & Wu, J. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01924 · Cited by 209
Yang, Y., Liu, X., Ma, W., Xu, Q., Chen, G., Wang, Y., Xiao, H., Li, N., Liang, X., Yu, M., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120456 · Cited by 211
Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer
Willers, H., Azzoli, C. G., Santivasi, W. L., & Xia, F. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318292e4e3 · Cited by 214
Development of liposomal formulations: From concept to clinical investigations
Fan, Y., & Zhang, Q. (2013) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.07.010 · Cited by 207
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
Song, M., Cui, M., & Liu, K. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114205 · Cited by 219
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
Molinaro, C., Martoriati, A., Pélinski, L., & Cailliau, K. (2020) · Cancers · doi:10.3390/cancers12102863 · Cited by 205
Zhang, K., Erkan, E. P., Jamalzadeh, S., Dai, J., Andersson, N., Kaipio, K., Lamminen, T., Mansuri, N., Huhtinen, K., Carpén, O., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm1831 · Cited by 202
Cruz‐Bermúdez, A., Briviesca, R. L., Vicente-Blanco, R. J., García‐Grande, A., Coronado, M. J., Laine-Menéndez, S., Palacios-Zambrano, S., Moreno-Villa, M. R., Ruiz-Valdepeñas, A. M., Lendinez, C., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.03.009 · Cited by 201
Li, F., Liu, J., Bao, R., Yan, G., Feng, X., Xu, Y., Sun, Y., Yan, W., Ling, Z., Xiong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02950-5 · Cited by 203
In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes
Knopf, K. M., Murphy, B. L., MacMillan, S. N., Baskin, J. M., Barr, M. P., Boros, E., & Wilson, J. J. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08640 · Cited by 193
García‐Santisteban, I., Peters, G. J., Giovannetti, E., & Rodríguez, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-91 · Cited by 191
Emerging role of NRF2 in ROS-mediated tumor chemoresistance
Xue, D., Zhou, X., & Qiu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110676 · Cited by 195
miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1
Shang, Y., Zhang, Z., Liu, Z., Feng, B., Ren, G., Li, K.-J., Zhou, L., Sun, Y., Li, M., Zhou, J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.297 · Cited by 189
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H. M., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 188
Precision medicine in head and neck cancer.
Kaidar-Person, O., Gil, Z., & Billan, S. (2018) · Drug resistance updates · doi:10.1016/j.drup.2018.09.001 · Cited by 169
Wang, Z., Wang, N., Cheng, S., Xu, K., Deng, Z., Chen, S., Xu, Z., Xie, K., Tse, M., Shi, P., et al. (2019) · Chem · doi:10.1016/j.chempr.2019.08.021 · Cited by 186
Collagen VI disorders: Insights on form and function in the extracellular matrix and beyond
Lamandé, S. R., & Bateman, J. F. (2017) · Matrix Biology · doi:10.1016/j.matbio.2017.12.008 · Cited by 184
Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies
Callejo, À., Sedó-Cabezón, L., Juan, I. D., & Llorens, J. (2015) · Toxics · doi:10.3390/toxics3030268 · Cited by 184
Zhang, P., Ma, Y., Lv, C., Huang, M., Li, M., Dong, B., Liu, X., An, G., Zhang, W., Zhang, J., et al. (2016) · Cancer Science · doi:10.1111/cas.13072 · Cited by 182
The role of ABC transporters in ovarian cancer progression and chemoresistance
Ween, M. P., Armstrong, M., Oehler, M. K., & Ricciardelli, C. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.012 · Cited by 188
Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System
Min, Y., Mao, C., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012) · Angewandte Chemie · doi:10.1002/ange.201201562 · Cited by 182
Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results
Mut‐Salud, N., Alvarez, P. J., Garrido, J. M., Carrasco, E., Aránega, A., & Rodríguez‐Serrano, F. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/6719534 · Cited by 187
Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs
Xu, Z., Wang, Z., Deng, Z., & Zhu, G. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213991 · Cited by 180
He, J., Yu, J.-J., Xu, Q., Wang, L., Zheng, J. Z., Liu, L.-Z., & Jiang, B. (2015) · Autophagy · doi:10.1080/15548627.2015.1009781 · Cited by 183
Cisplatin Resistance Associated with PARP Hyperactivation
Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K. A., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D. P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3000 · Cited by 176
Self-citationGlutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis
Zhu, Z., Du, S., Du, Y., Ren, J., Ying, G., & Zhao, Y. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14250 · Cited by 176
NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells
Jiang, P., Wu, X., Xuemin, W., Huang, W., & Feng, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.9712 · Cited by 174
Mitochondrial Transfer in Cancer: A Comprehensive Review
Zampieri, L. X., Silva‐Almeida, C., Rondeau, J. D., & Sonveaux, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063245 · Cited by 179
Polymer encapsulation of ruthenium complexes for biological and medicinal applications
Villemin, E., Ong, Y. C., Thomas, C. M., & Gasser, G. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0088-0 · Cited by 176
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
Pujade-Lauraine, É., Banerjee, S. N., & Pignata, S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00194 · Cited by 170
Nie, S., Zhang, L., Liu, J., Wan, Y., Jiang, Y., Yang, J., Sun, R., Ma, X., Sun, G., Meng, H., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02088-1 · Cited by 166
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 175
Nogales, V., Reinhold, W. C., Varma, S., Martínez‐Cardús, A., Moutinho, C., Morán, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y. G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6413 · Cited by 176
Sarin, N., Engel, F., Kalayda, G. V., Mannewitz, M., Cinatl, J. J., Rothweiler, F., Michaelis, M., Saafan, H., Ritter, C. A., Jaehde, U., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181081 · Cited by 169
Pro-survival autophagy and cancer cell resistance to therapy
Das, C. K., Mandal, M., & Kögel, D. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9727-z · Cited by 172
Yousuf, I., Bashir, M., Arjmand, F., & Tabassum, S. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214104 · Cited by 167
Rocha, C. R. R., Garcia, C. C. M., Vieira, D. B., Quinet, A., de Andrade-Lima, L. C., Munford, V., Belizário, J. E., & Menck, C. F. M. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.465 · Cited by 163
Kamatchi, T. S., Subarkhan, M. K. M., Ramesh, R., Wang, H., & Małecki, J. G. (2020) · Dalton Transactions · doi:10.1039/d0dt01476a · Cited by 165
Metadata
- Authors
- Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Université Paris-Sud (FR)
- Corresponding author
- Kroemer, G
- Venue
- Oncogene
- Published
- 2011-09-05
- Volume
- 31
- Issue
- 15
- Pages
- 1869-1883
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2141037581
- Cited by
- 2,760
- References
- 196
- Citations by year
- 2026: 154 · 2025: 187 · 2024: 244 · 2023: 220 · 2022: 247 · 2021: 308 · 2020: 252 · 2019: 213 · 2018: 169 · 2017: 167 · 2016: 159 · 2015: 160 · 2014: 145 · 2013: 89 · 2012: 44
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Ligue Contre le Cancer
- Fondation Bettencourt Schueller
- Labex Immuno-Oncology
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin resistance, chemoresistance, platinum anticancer drugs, DNA damage response, mitochondrial apoptosis, chemosensitization, DNA lesions
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Signal Transduction, DNA Adducts, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
